From Compliance to Consequence: Is Your Board understanding & responding risk

In 2026, the “corporate” and “clinical” sides of aged care are no longer separate silos. Under the Aged Care Act 2024, the Governing body is accountable for the clinical outcomes via the delivery of funded aged care services. The introduction of the Statutory Duty means that if a systemic clinical failure occurs—such as a widespread outbreak or a pattern of neglected pressure injuries—the Board must prove they exercised “due diligence” to prevent it.

The Clinical-to-Boardroom Pipeline

The 2026 regulatory model requires a “Golden Thread” of information. Boards can no longer rely on vague assurances that “everything is fine.” Registered providers  must have a Clinical Governance Framework that provides real-time data on high-impact risks. This includes monitoring the use of psychotropic medications, weight loss trends, and the prevalence of Stage 3 or 4 pressure sores.

Under the Strengthened Quality Standards, specifically Standard 1 (The Person) and Standard 5 (Clinical Care), the governing body must demonstrate that it has prioritised “Dignity of Risk.” This is the clinical governance challenge of the decade: how does a Board oversee a system that allows an older person to take calculated risks (like choosing to walk unaided despite a high fall risk) while still meeting safety obligations?

A key element of demonstrating “due diligence” involves the governing body’s thorough understanding and interrogation of National Quality Indicator (NQI) performance results. These indicators are key, as they provide a direct, benchmarkable measure of the provider’s clinical outcomes against the national standard and peer group—a requirement soon to be extended to Support at Home services. Boards must actively track NQI trends to assess the efficacy of risk mitigation strategies and improvement initiatives. The ability of the Board to work collaboratively with management, using this data to inform strategic priorities and deployment of resources, is the hallmark of effective clinical governance, ensuring that systemic issues are proactively addressed rather than simply reacted to.

The Role of the Clinical Governance

By 2026, most providers will have moved beyond the minimum requirement of having one board member with clinical experience. Leading organisations have established robust Clinical Governance Committees that include external experts, geriatricians, and consumer representatives. These committees act as the “engine room” for quality, translating complex clinical data into strategic actions for the Board.

Governance Calls to Action

1. Define Your “Clinical Risk Appetite”: Does your Board have a formal statement on how you balance resident autonomy with safety? If not, schedule a workshop to define your organisation’s stance on “Dignity of Risk.” Build your bench strength in understanding High Impact Risk
2. Verify Clinical Data Integrity: Arrange a third line external review of your clinical reporting systems. Ensure the data reaching the Board accurately reflects the reality at the bedside.
3. Clinical Governance – Is your framework delivering your model of care and addressing High Impact risk, how are the NQIs tracking?
4. Enable an effective Quality Care Advisory Body: Ensure this body is not just a “talking shop” but has a direct, documented pathway to provide feedback to the Board on clinical safety concerns.